Authors' reply to Alatorre et al.: "cost effectiveness of guanfacine extended-release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder: application of a matching-adjusted indirect comparison".

We thank Dr Alatorre and co-authors for their letter [1] regarding our manuscript entitled “Cost effectiveness of guanfacine extended-release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder: application of a matching-adjusted indirect comparison”, which was published in the November 1, 2012 issue of Applied Health Economics and Health Policy [2].

We have conducted a thorough review of the manuscript and supportive study analyses from which it stems. We have found that some numbers in Table III were transposed in the published manuscript. The erratum [3] is published to correct these errors.

We apologize for the errors and confirm that these errors are typographical in nature and do not affect the results, discussion or conclusion in the originally published manuscript [2].